Single User
£3750
PDF
82 pages

Leukaemia Forecast in 18 Major Markets 2017-2027


Leukaemia refers to a group of cancers which originate in the bone marrow; they result in the overproduction of abnormal white blood cells. This limits the bone marrows ability to produce normal and fully mature white blood cells. Leukaemia classification is based on the speed of disease progression and the type of cells involved. The main subtypes are myeloid and monocytic, lymphoid or other; these can then be further subdivided into groups such as 'Acute' or 'Chronic'. Acute and chronic refer to the speed of disease progression. Whereas, myeloid, monocytic and lymphoid refer to the cell type affected.

This report provides the current incidence population for Leukaemia across 18 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Brazil, Japan, India, China, Turkey, Mexico, Russia, Argentina, Australia, Saudi Arabia and South Africa) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Leukaemia have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Leukaemia include:

  • Haemolytic Anaemia
  • Diabetes
  • Frequent infections
  • Headaches
  • Cachexia

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy
  • Able to quantify patient populations in global Leukaemia market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the incidence of the subdivided types of Leukaemia and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on Leukaemia incident population.
  • Identify sub-populations within Leukaemia which require treatment.
  • Gain an understanding of the specific markets that have the largest number of Leukaemia patients.
Table of Contents
  • List of Tables and Figures
  • Introduction
  • Cause of the Disease
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Variation by Geography/Ethnicity
  • Disease Prognosis & Clinical Course
  • Key comorbid features associated with the disease
  • Methodology for quantification of patient numbers
  • Top-line Incidence for Leukaemia
  • Type of Leukaemia
  • Lymphocytic Leukaemia
    • Acute Lymphocytic Leukaemia
    • Chronic Lymphocytic Leukaemia
  • Myeloid & Monocytic Leukaemia
    • Chronic Myeloid Leukaemia
  • Other Types of Leukaemia
  • Treatment Rates
  • Abbreviations used in the Report
  • Other Black Swan Analysis Publications
  • Black Swan Analysis Online Patient-Based Databases
  • Patient-Based Offering
  • Online Pricing Data and Platforms
  • References
  • Appendix
List of Tables
  • The Rai staging system for CLL
  • CML Prognostic scores
  • Incidence of leukaemia, total (000s)
  • Incidence of leukaemia, males (000s)
  • Incidence of leukaemia, females (000s)
  • Type of Leukaemia, total (000s)
  • Type of Lymphocytic Leukaemia, total (000s)
  • Subtype of Acute lymphocytic Leukaemia, total (000s)
  • Philadelphia chromosome abnormality in ALL patients, total (000s)
  • CLL patients by Rai Stage, total (000s)
  • CLL patients with 17p Deletion, total (000s)
  • CLL patients with Haemolytic anaemia, total (000s)
  • Type of Myeloid/ Monocytic Leukaemia, total (000s)
  • Type of CML, total (000s)
  • Phase at Diagnosis of CML patients, total (000s)
  • CML patients by Sokal Risk Score, total (000s)
  • CML patients by Hasford Risk Score, total (000s)
  • Spleen size, total (000s)
  • Other Leukaemias, total (000s)
  • CLL treated patients by line of therapy, total (000s)
  • CML treated patients by line of therapy, total (000s)
  • Abbreviations and Acronyms used in the report
  • USA Incidence of Leukaemia by 5-yr age cohort, males (000s)
  • USA Incidence of Leukaemia by 5-yr age cohort, females (000s)
  • Canada Incidence of Leukaemia by 5-yr age cohort, males (000s)
  • Canada Incidence of Leukaemia by 5-yr age cohort, females (000s)
  • France Incidence of Leukaemia by 5-yr age cohort, males (000s)
  • France Incidence of Leukaemia by 5-yr age cohort, females (000s)
  • Germany Incidence of Leukaemia by 5-yr age cohort, males (000s)
  • Germany Incidence of Leukaemia by 5-yr age cohort, females (000s)
  • Italy Incidence of Leukaemia by 5-yr age cohort, males (000s)
  • Italy Incidence of Leukaemia by 5-yr age cohort, females (000s)
  • Spain Incidence of Leukaemia by 5-yr age cohort, males (000s)
  • Spain Incidence of Leukaemia by 5-yr age cohort, females (000s)
  • UK Incidence of Leukaemia by 5-yr age cohort, males (000s)
  • UK Incidence of Leukaemia by 5-yr age cohort, females (000s)
  • Brazil Incidence of Leukaemia by 5-yr age cohort, males (000s)
  • Brazil Incidence of Leukaemia by 5-yr age cohort, females (000s)
  • Japan Incidence of Leukaemia by 5-yr age cohort, males (000s)
  • Japan Incidence of Leukaemia by 5-yr age cohort, females (000s)
  • India Incidence of Leukaemia by 5-yr age cohort, males (000s)
  • India Incidence of Leukaemia by 5-yr age cohort, females (000s)
  • China Incidence of Leukaemia by 5-yr age cohort, males (000s)
  • China Incidence of Leukaemia by 5-yr age cohort, females (000s)
  • Turkey Incidence of Leukaemia by 5-yr age cohort, males (000s)
  • Turkey Incidence of Leukaemia by 5-yr age cohort, females (000s)
  • Australia Incidence of Leukaemia by 5-yr age cohort, males (000s)
  • Australia Incidence of Leukaemia by 5-yr age cohort, females (000s)
  • Mexico Incidence of Leukaemia by 5-yr age cohort, males (000s)
  • Mexico Incidence of Leukaemia by 5-yr age cohort, females (000s)
  • Argentina Incidence of Leukaemia by 5-yr age cohort, males (000s)
  • Argentina Incidence of Leukaemia by 5-yr age cohort, females (000s)
  • Russia Incidence of Leukaemia by 5-yr age cohort, males (000s)
  • Russia Incidence of Leukaemia by 5-yr age cohort, females (000s)
  • Saudi Arabia Incidence of Leukaemia by 5-yr age cohort, males (000s)
  • Saudi Arabia Incidence of Leukaemia by 5-yr age cohort, females (000s)
  • South Africa Incidence of Leukaemia by 5-yr age cohort, males (000s)
  • South Africa Incidence of Leukaemia by 5-yr age cohort, females (000s)
Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Russian Federation, Saudi Arabia, South Africa, Spain, Turkey, United Kingdom, United States of America